Georgina Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Georgina Yan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Annalie Shears
Brighton and Sussex Medical School, University of Sussex and University of Brighton, Brighton, United Kingdom; Department of Paediatrics, University Hospitals Sussex, Brighton, United Kingdom; The Health Research Unit Zimbabwe, Biomedical Research and Training Institute, Harare, Zimbabwe
4 shared publications - Julia Dudley
Academic Department of Paediatrics, Royal Alexandra Children’s Hospital, Brighton, West Sussex, UK
3 shared publications - Katy Fidler
Medical Research Building, Brighton and Sussex Medical School, Brighton, England, UK
3 shared publications - Paul Trafford Heath
Centre for Neonatal and Paediatric Infection and Vaccine Institute, City St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK
3 shared publications Katy J Fidler
Academic Department of Paediatrics, Royal Alexandra Children's Hospital, Brighton, UK
2 shared publicationsElizabeth Cross
Department of Infectious Diseases, University Hospitals Sussex NHS Foundation Trust, Brighton, UK
1 shared publication
Latest Publications
- 13 April 2026
- Published by BMJ in Archives of Disease in Childhood
Incidence of herpes simplex infection among febrile infants under 3 months of age: evidence from two multisite cohorts
The prevalence of invasive bacterial infection in young febrile infants is estimated at 1%–4%, with the highest rates in those <21 days.1 UK guidelines recommend screening all febrile neonates for bacterial infection and starting empiric broad-spectrum antibiotics while awaiting results,2–4 but not routine antiviral therapy. However, a recent UK/Ireland prospective surveillance study reported an increased incidence of neonatal herpes simplex virus (HSV) infection of 6.0 per 100 000 live births, with substantial associated morbidity and mortality.5
- 13 April 2026
- Published by BMJ in Archives of Disease in Childhood
Incidence of herpes simplex infection among febrile infants under 3 months of age: evidence from two multisite cohorts
The prevalence of invasive bacterial infection in young febrile infants is estimated at 1%–4%, with the highest rates in those <21 days.1 UK guidelines recommend screening all febrile neonates for bacterial infection and starting empiric broad-spectrum antibiotics while awaiting results,2–4 but not routine antiviral therapy. However, a recent UK/Ireland prospective surveillance study reported an increased incidence of neonatal herpes simplex virus (HSV) infection of 6.0 per 100 000 live births, with substantial associated morbidity and mortality.5
- 1 September 2025
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (5) , 423-429
Herpes simplex virus disease in infants younger than 90 days: a British Paediatric Surveillance Unit study
Objective: Estimate the incidence of herpes simplex virus (HSV) infections in infants under 90 days in the UK and Ireland and describe clinical presentation and outcomes. Design: Prospective population-based national surveillance study of infants <90 days with HSV infection, using British Paediatric Surveillance Unit (BPSU) methodology (August 2019–February 2022). Results: 117 infants with confirmed HSV infection were identified (6.0 cases/100 000 live births (95% CI 4.9, 7.2)). One-third (34.5%) of infants were premature (24 hours after symptom onset. Infants with disseminated infections presented with non-specific signs of sepsis: 65.8% were afebrile and 73.7% had no SEM lesions. Median C reactive protein at presentation was 4 mg/L (IQR 1–14). Overall mortality was 23.9%, rising to 65.8% among infants with disseminated disease. Of the 41 infants with follow-up data at 24 months, 29.3% had neurodevelopmental impairment (11.8% SEM, 45% CNS, 25% disseminated). Conclusions: Infants with neonatal HSV can present without fever, SEM lesions or elevated infection markers; treatment delay is subsequently common. Outcomes remain poor with high case-fatality rates and long-term morbidity. Clinicians should have a low threshold for empirically testing for and treating herpes in unwell neonates.
- 1 September 2025
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (5) , 423-429
Herpes simplex virus disease in infants younger than 90 days: a British Paediatric Surveillance Unit study
Objective: Estimate the incidence of herpes simplex virus (HSV) infections in infants under 90 days in the UK and Ireland and describe clinical presentation and outcomes. Design: Prospective population-based national surveillance study of infants <90 days with HSV infection, using British Paediatric Surveillance Unit (BPSU) methodology (August 2019–February 2022). Results: 117 infants with confirmed HSV infection were identified (6.0 cases/100 000 live births (95% CI 4.9, 7.2)). One-third (34.5%) of infants were premature (24 hours after symptom onset. Infants with disseminated infections presented with non-specific signs of sepsis: 65.8% were afebrile and 73.7% had no SEM lesions. Median C reactive protein at presentation was 4 mg/L (IQR 1–14). Overall mortality was 23.9%, rising to 65.8% among infants with disseminated disease. Of the 41 infants with follow-up data at 24 months, 29.3% had neurodevelopmental impairment (11.8% SEM, 45% CNS, 25% disseminated). Conclusions: Infants with neonatal HSV can present without fever, SEM lesions or elevated infection markers; treatment delay is subsequently common. Outcomes remain poor with high case-fatality rates and long-term morbidity. Clinicians should have a low threshold for empirically testing for and treating herpes in unwell neonates.
- Open Access
- 11 May 2022
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 107 (6) , 630-636
Vestibular and balance dysfunction in children with congenital CMV: a systematic review
Objective This systematic review evaluates vestibular and balance dysfunction in children with congenital cytomegalovirus (cCMV), makes recommendations for clinical practice and informs future research priorities. Design MEDLINE, Embase, EMCARE, BMJ Best Practice, Cochrane Library, DynaMed Plus and UpToDate were searched from inception to 20 March 2021 and graded according to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria. Patients Children with cCMV diagnosed within 3 weeks of life from either blood, saliva and/or urine (using either PCR or culture). Intervention Studies of vestibular function and/or balance assessments. Main outcome measures Vestibular function and balance. Results 1371 studies were identified, and subsequently 16 observational studies were eligible for analysis, leading to an overall cohort of 600 children with cCMV. All studies were of low/moderate quality. In 12/16 studies, vestibular function tests were performed. 10/12 reported vestibular dysfunction in ≥40% of children with cCMV. Three studies compared outcomes for children with symptomatic or asymptomatic cCMV at birth; vestibular dysfunction was more frequently reported in children with symptomatic (22%–60%), than asymptomatic cCMV (0%–12.5%). Two studies found that vestibular function deteriorated over time: one in children (mean age 7.2 months) over 10 months and the other (mean age 34.7 months) over 26 months. Conclusions Vestibular dysfunction is found in children with symptomatic and asymptomatic cCMV and in those with and without hearing loss. Audiovestibular assessments should be performed as part of neurodevelopmental follow-up in children with cCMV. Case–controlled longitudinal studies are required to more precisely characterise vestibular dysfunction and help determine the efficacy of early supportive interventions. PROSPERO registration CRD42019131656.
- 11 May 2022
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 107 (6) , 630-636
Open AccessVestibular and balance dysfunction in children with congenital CMV: a systematic review
Objective This systematic review evaluates vestibular and balance dysfunction in children with congenital cytomegalovirus (cCMV), makes recommendations for clinical practice and informs future research priorities. Design MEDLINE, Embase, EMCARE, BMJ Best Practice, Cochrane Library, DynaMed Plus and UpToDate were searched from inception to 20 March 2021 and graded according to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria. Patients Children with cCMV diagnosed within 3 weeks of life from either blood, saliva and/or urine (using either PCR or culture). Intervention Studies of vestibular function and/or balance assessments. Main outcome measures Vestibular function and balance. Results 1371 studies were identified, and subsequently 16 observational studies were eligible for analysis, leading to an overall cohort of 600 children with cCMV. All studies were of low/moderate quality. In 12/16 studies, vestibular function tests were performed. 10/12 reported vestibular dysfunction in ≥40% of children with cCMV. Three studies compared outcomes for children with symptomatic or asymptomatic cCMV at birth; vestibular dysfunction was more frequently reported in children with symptomatic (22%–60%), than asymptomatic cCMV (0%–12.5%). Two studies found that vestibular function deteriorated over time: one in children (mean age 7.2 months) over 10 months and the other (mean age 34.7 months) over 26 months. Conclusions Vestibular dysfunction is found in children with symptomatic and asymptomatic cCMV and in those with and without hearing loss. Audiovestibular assessments should be performed as part of neurodevelopmental follow-up in children with cCMV. Case–controlled longitudinal studies are required to more precisely characterise vestibular dysfunction and help determine the efficacy of early supportive interventions. PROSPERO registration CRD42019131656.
- Open Access
- 30 September 2021
- Published by BMJ
- Vol. 106 (Suppl 1) , A390-A391
1487 Neonatal HSV disease in infants under 90 days of age in UK and Ireland: BPSU study interim analysis
Background Neonatal herpes simplex virus infection is a rare but dangerous condition with a high mortality and morbidity unless recognised and treated early. A recent study1 suggests that the UK incidence may have increased since the last national surveillance studies were undertaken 15 and 30 years ago.2,3 There is currently no national guidance on when to initiate treatment for suspected neonatal HSV. Rising numbers of HSV cases may support the wider use of empirical treatment. Objectives To define the: (1) current burden of HSV disease and virus types, in UK and Irish infants less than 90 days, over a two-year period, (2) types of HSV disease ie disseminated, meningoencephalitis or skin/eye/mouth disease, (3) presentations and management, (4) source of transmission, (5) antenatal risk factors. Methods Prospective surveillance of HSV infection in infants < 90 days of age in UK and Ireland commenced in July 2019 through the British Paediatric Surveillance Unit (BPSU). Paediatricians reporting cases were requested to complete a detailed semi-anonymised questionnaire. Case notifications & data from completed questionnaires during the first 18 months, July 2019 - Jan 2021, are reported here. Results 137 cases reported to BPSU: 8 were errors, 80 clinicians completed questionnaires, 21 confirmed duplicates, leaving 59 cases for analysis. Estimated incidence is 6.9 cases per 100 000 live births based on 2019 UK & Ireland birth rates. 31 (53%) male, 17 (29%) born Conclusions Incidence of neontatal HSV has doubled since the last national surveillance study. Mortality remains high and presenting features of disseminated disease are non-specific. Absence of fever in 86% of cases demonstrates that HSV should not only be considered in the assessment of the febrile infant. Awareness of this disease needs to be raised to enable early recognition and treatment. References Batra D, Davies P, Manktelow BN, et al. The incidence and presentation of neonatal herpes in a single UK tertiary centre, 2006–2013. Archives of Disease in Childhood 2014;99:916–921. Tookey P, et al. Surveillance of neonatal herpes in the British Isles 2004–2006. Submitted for publication. Tookey P1, Peckham CS. Neonatal herpes simplex virus infection in the British Isles. Paediatr Perinat Epidemiol 1996 Oct;10(4):432–42.
- 30 September 2021
- Published by BMJ
- Vol. 106 (Suppl 1) , A390-A391
Open Access1487 Neonatal HSV disease in infants under 90 days of age in UK and Ireland: BPSU study interim analysis
Background Neonatal herpes simplex virus infection is a rare but dangerous condition with a high mortality and morbidity unless recognised and treated early. A recent study1 suggests that the UK incidence may have increased since the last national surveillance studies were undertaken 15 and 30 years ago.2,3 There is currently no national guidance on when to initiate treatment for suspected neonatal HSV. Rising numbers of HSV cases may support the wider use of empirical treatment. Objectives To define the: (1) current burden of HSV disease and virus types, in UK and Irish infants less than 90 days, over a two-year period, (2) types of HSV disease ie disseminated, meningoencephalitis or skin/eye/mouth disease, (3) presentations and management, (4) source of transmission, (5) antenatal risk factors. Methods Prospective surveillance of HSV infection in infants < 90 days of age in UK and Ireland commenced in July 2019 through the British Paediatric Surveillance Unit (BPSU). Paediatricians reporting cases were requested to complete a detailed semi-anonymised questionnaire. Case notifications & data from completed questionnaires during the first 18 months, July 2019 - Jan 2021, are reported here. Results 137 cases reported to BPSU: 8 were errors, 80 clinicians completed questionnaires, 21 confirmed duplicates, leaving 59 cases for analysis. Estimated incidence is 6.9 cases per 100 000 live births based on 2019 UK & Ireland birth rates. 31 (53%) male, 17 (29%) born Conclusions Incidence of neontatal HSV has doubled since the last national surveillance study. Mortality remains high and presenting features of disseminated disease are non-specific. Absence of fever in 86% of cases demonstrates that HSV should not only be considered in the assessment of the febrile infant. Awareness of this disease needs to be raised to enable early recognition and treatment. References Batra D, Davies P, Manktelow BN, et al. The incidence and presentation of neonatal herpes in a single UK tertiary centre, 2006–2013. Archives of Disease in Childhood 2014;99:916–921. Tookey P, et al. Surveillance of neonatal herpes in the British Isles 2004–2006. Submitted for publication. Tookey P1, Peckham CS. Neonatal herpes simplex virus infection in the British Isles. Paediatr Perinat Epidemiol 1996 Oct;10(4):432–42.